HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

9.460

+0.0600.64%

Volume:2.18M

Turnover:20.38M

Market Cap:3.85B

PE:-10.66

High:9.490

Open:9.445

Low:9.255

Close:9.400

52wk High:679.500

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.56

T/O Rate:0.70%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.888

ROE:-36.78%

ROA:-20.32%

PB:3.75

PE(LYR):-10.66

PS:92.98

Loading ...

Overview Company News Filings

TRANSTHERA-B Receives Regulatory Nod for Phase II Trial of TT-00973 in Combination with Furmonertinib for NSCLC

TransThera gains NMPA clearance to launch Phase II study of TT-00973 plus firmonertinib in EGFR-mutant NSCLC

Bulletin Express

Transthera Sciences (nanjing) - Nmpa Approves Phase Ii Trial of Tt-973 with Firmonertinib Mesylate on July 10, 2026

THOMSON REUTERS

Movement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib

Movement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan

Movement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval

From $270 Billion to $4.1 Billion: This Small Biotech, With Just Over 100 Employees, Is Undertaking What Giants Dare Not Attempt

Movement Alert｜TransThera Sciences Rises 6.93% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment and New Pipeline Gains Approval

TransThera Sciences Completes Patient Enrollment for Cholangiocarcinoma Drug Trial

MT Newswires Live

TRANSTHERA-B Secures Regulatory Approval for Phase II Trial of TT-01488 Combination Therapy in Mantle Cell Lymphoma

TransThera Sciences gains NMPA nod for Phase II study of BTK inhibitor TT-01488 plus anti-CD20 antibody in mantle cell lymphoma

Bulletin Express

TransThera Sciences Completes Enrollment for Global Phase III Tinengotinib Trial in Advanced Cholangiocarcinoma

Bulletin Express

Transthera Completes Enrollment in Phase III Tinengotinib Trial for Advanced Cholangiocarcinoma

Transthera Says China Regulator Clears Phase II Trial of Tt-01488 Combo in Mantle Cell Lymphoma

Movement Alert｜TransThera Sciences-B Intraday Decline 8.18%, Buyback Plan Boost Fades as Post-Lockup Selling Pressure Persists

Movement Alert｜TransThera Sciences-B Rises 19.89% in Regular Trading, Company Announces Up to RMB 100 Million H-Share Buyback Plan

Transthera Sciences Jumps Most in Nearly Four Months on Share Buyback Plan

HK Movers | Hong Kong Biotech Sector Strengthened; TRANSTHERA Rose More Than 20%

Tiger Newspress

TRANSTHERA-B Announces Market Buyback Plan Under General Mandate

TransThera Sciences plans on-market buyback of up to RMB100.00 million under existing mandate

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/02617/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":9.46,"timestamp":1789027724004,"preClose":9.4,"halted":0,"volume":2176000,"delay":0,"changeRate":0.006382978723404308,"floatShares":312000000,"shares":407000000,"eps":-0.8876291748025816,"marketStatus":"Not Yet Opened","change":0.06,"latestTime":"09-10 16:08:44","open":9.445,"high":9.49,"low":9.255,"amount":20379607,"amplitude":0.025,"askPrice":9.46,"askSize":5000,"bidPrice":9.455,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-0.7855214534390415,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":9.4,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.563016,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-20.32%","roe":"-36.78%","lyrEps":-0.887629,"volumeRatio":0.563016,"shares":407000000,"dividePrice":0,"high":9.49,"amplitude":0.025,"preClose":9.4,"low":9.255,"week52Low":9.01,"pbRate":"3.75","psRate":"92.98","week52High":679.5,"institutionHeld":0,"latestPrice":9.46,"committee":0.6,"eps":-0.8876291748025816,"divideRate":0,"volume":2176000,"delay":0,"ttmEps":-0.7855214534390415,"open":9.445,"prevYearClose":114.9,"prevWeekClose":10.15,"prevMonthClose":10.17,"prevQuarterClose":11.55,"fiveDayClose":10.09,"twentyDayClose":10.66,"sixtyDayClose":29.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-09-09","current":-11.933351,"percent":0.94,"low":-380.446233,"twenty":-196.609225,"median":-71.813981,"eighty":-33.547213,"high":-10.87103,"avg":-110.355125,"sd":96.342477,"marketCap":3834435150},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-28","current":-13.544101,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"marketCap":4242353783},{"date":"2026-09-04","current":-13.213217,"twenty":-200.748681,"median":-72.756691,"eighty":-35.040401,"marketCap":4140374124},{"date":"2026-09-09","current":-12.217317,"twenty":-196.609225,"median":-71.813981,"eighty":-33.547213,"marketCap":3834435150}],"updateTime":1789025884859},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1167220060","title":"TRANSTHERA-B Receives Regulatory Nod for Phase II Trial of TT-00973 in Combination with Furmonertinib for NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1167220060","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167220060?lang=en_us&edition=fundamental","pubTime":"2026-07-10 22:24","pubTimestamp":1783693470,"startTime":"0","endTime":"0","summary":"Clinical trial approval has been granted for a Phase II study of TRANSTHERA-B's (ASX: 02617) investigational drug TT-00973 in combination with furmonertinib for a specific type of lung cancer.The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2720916845.USD","LU2463526074.USD","LU2552382215.SGD","LU2279689827.SGD","BK1161","LU2552382132.HKD","LU2764263203.CNY","LU1718418525.SGD","LU2133065610.SGD","BK4588","LU0070217475.USD","LU0154245673.USD","LU2347655156.SGD","TT","LU0266013472.USD","LU0323239441.USD","LU1732799900.SGD","BMED","IE0004086264.USD","IE0004091025.USD","LU0795875086.SGD","SG9999002224.SGD","LU0238689110.USD","LU0726765562.USD","LU1732800096.USD","LU2089279066.USD","LU2347655073.USD","IE00B2PGVK34.USD","IE00B3CCJ633.GBP","LU2211814178.USD","LU2211817866.USD","SG9999002232.USD","IBBQ","02617","LU0323240290.USD","LU0210533765.USD","LU2764262908.HKD","IE00BKVL7J92.USD","LU0795875169.SGD","IE00BGHQF417.EUR","IE00BZ1G4Q59.USD","BK4585","LU0912757837.SGD","BK4086","LU2229751404.USD","LU2394011477.USD","LU2552382058.USD","LU2764263039.SGD","BK4533","LU0154245756.USD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184982898","title":"TransThera gains NMPA clearance to launch Phase II study of TT-00973 plus firmonertinib in EGFR-mutant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1184982898","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184982898?lang=en_us&edition=fundamental","pubTime":"2026-07-10 22:23","pubTimestamp":1783693419,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera, HKEX: 02617) has secured National Medical Products Administration approval, dated 10 July 2026, to initiate a multi-centre, open-label Phase II trial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650135665","title":"Transthera Sciences (nanjing) - Nmpa Approves Phase Ii Trial of Tt-973 with Firmonertinib Mesylate on July 10, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650135665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650135665?lang=en_us&edition=fundamental","pubTime":"2026-07-10 22:18","pubTimestamp":1783693085,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C0FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185228112","title":"Movement Alert｜TransThera Sciences-B Rises 8.18% in Regular Trading, Phase III Trial Enrollment Completed for Core Product Tinengotinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1185228112","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185228112?lang=en_us&edition=fundamental","pubTime":"2026-07-10 11:12","pubTimestamp":1783653127,"startTime":"0","endTime":"0","summary":"On July 10, TransThera Sciences-B rose 8.18% in regular trading, reaching HK$11.11 per share, with turnover of HK$143 million.On the news front, the company announced on July 1 that its core product...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135423515","title":"Movement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1135423515","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135423515?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:30","pubTimestamp":1783305047,"startTime":"0","endTime":"0","summary":"On July 6, TransThera Sciences-B rose 6.19% in regular trading, trading at HK$12.56/share, with turnover of HK$136 million. The stock was lifted by a broad biotech sector rally alongside...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103684444","title":"Movement Alert｜TransThera Sciences Rises 5.33% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment Plus New Pipeline Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1103684444","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103684444?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:51","pubTimestamp":1783043474,"startTime":"0","endTime":"0","summary":"On July 3, TransThera Sciences-B rose 5.33% in regular trading, trading at HK$12.52/share, with turnover of HK$84.94 million. The stock continues its upward momentum following key R&D milestones...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127655442","title":"From $270 Billion to $4.1 Billion: This Small Biotech, With Just Over 100 Employees, Is Undertaking What Giants Dare Not Attempt","url":"https://stock-news.laohu8.com/highlight/detail?id=1127655442","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127655442?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:27","pubTimestamp":1782984462,"startTime":"0","endTime":"0","summary":"The market valuation of TRANSTHERA-B (02617) has plummeted from a historical peak of HK$270 billion to approximately HK$4.1 billion. On June 23rd, the company entered the second phase of a post-IPO...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156797201","title":"Movement Alert｜TransThera Sciences Rises 6.93% in Regular Trading, Core Product Tinengotinib Phase III Trial Completes Enrollment and New Pipeline Gains Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1156797201","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156797201?lang=en_us&edition=fundamental","pubTime":"2026-07-02 10:25","pubTimestamp":1782959132,"startTime":"0","endTime":"0","summary":"On July 2, TransThera Sciences-B (02617.HK) rose 6.93% in regular trading, reaching HK$12.29 per share, with turnover of HK$317 million.On the news front, the company released two R&D progress...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648543329","title":"TransThera Sciences Completes Patient Enrollment for Cholangiocarcinoma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648543329","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648543329?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:32","pubTimestamp":1782909170,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) (HKG:2617) completed enrollment for a phase III trial of Tinengotinib.The drug is being tested for the treatment of patients with advanced cholangiocarcinoma, according to a Wednesday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165007087","title":"TRANSTHERA-B Secures Regulatory Approval for Phase II Trial of TT-01488 Combination Therapy in Mantle Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1165007087","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165007087?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:38","pubTimestamp":1782905913,"startTime":"0","endTime":"0","summary":"The China National Medical Products Administration (NMPA) has granted approval for a Phase II clinical trial of TRANSTHERA-B's (ASX: 02617) product, TT-01488 tablets, in combination with an anti-CD20...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU0726765562.USD","LU2229751404.USD","BK4533","LU1718418525.SGD","SG9999002232.USD","LU1732799900.SGD","02617","TT","LU2720916845.USD","LU2279689827.SGD","BK1161","LU2463526074.USD","LU2764263203.CNY","IE00BKVL7J92.USD","LU0210533765.USD","BK4086","IE00BGHQF417.EUR","LU0238689110.USD","LU0323239441.USD","LU2347655156.SGD","IE0004091025.USD","LU2347655073.USD","LU2089279066.USD","IE00B3CCJ633.GBP","LU0070217475.USD","LU0795875086.SGD","LU0154245756.USD","BK4585","IE0004086264.USD","LU2552382058.USD","IE00B2PGVK34.USD","LU2764262908.HKD","SG9999002224.SGD","BK4504","LU2133065610.SGD","LU1732800096.USD","LU2764263039.SGD","LU2394011477.USD","BK1233","LU0795875169.SGD","LU0323240290.USD","BK4588","LU2211817866.USD","IE00BZ1G4Q59.USD","LU2211814178.USD","LU2552382215.SGD","LU0912757837.SGD","01488","LU2552382132.HKD","LU0154245673.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154644853","title":"TransThera Sciences gains NMPA nod for Phase II study of BTK inhibitor TT-01488 plus anti-CD20 antibody in mantle cell lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1154644853","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154644853?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:25","pubTimestamp":1782905141,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Stock Name: TRANSTHERA-B) announced that China’s National Medical Products Administration granted approval on 1 July 2026 for a Phase II clinical trial evaluating TT-01488...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134347564","title":"TransThera Sciences Completes Enrollment for Global Phase III Tinengotinib Trial in Advanced Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1134347564","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134347564?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:25","pubTimestamp":1782905102,"startTime":"0","endTime":"0","summary":"TransThera Sciences (TRANSTHERA-B, 02617) announced the completion of patient enrollment for its global, multicenter, registrational Phase III study evaluating Tinengotinib (TT-00420) monotherapy in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648179985","title":"Transthera Completes Enrollment in Phase III Tinengotinib Trial for Advanced Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2648179985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648179985?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:11","pubTimestamp":1782904317,"startTime":"0","endTime":"0","summary":"TransThera completes enrollment in Phase III tinengotinib trial for advanced cholangiocarcinomaTransthera Sciences (Nanjing) completed enrollment in a global, registrational Phase III trial of tinengo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL7yf7Yr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648173425","title":"Transthera Says China Regulator Clears Phase II Trial of Tt-01488 Combo in Mantle Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2648173425","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648173425?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:04","pubTimestamp":1782903848,"startTime":"0","endTime":"0","summary":"TransThera says China regulator clears Phase II trial of TT-01488 combo in mantle cell lymphomaTransthera Sciences received China NMPA clearance on July 1, 2026 to start a Phase II trial of TT-01488 t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL6bFrgH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111653620","title":"Movement Alert｜TransThera Sciences-B Intraday Decline 8.18%, Buyback Plan Boost Fades as Post-Lockup Selling Pressure Persists","url":"https://stock-news.laohu8.com/highlight/detail?id=1111653620","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111653620?lang=en_us&edition=fundamental","pubTime":"2026-06-30 11:00","pubTimestamp":1782788448,"startTime":"0","endTime":"0","summary":"On June 30, TransThera Sciences-B fell 8.18% in regular trading, trading at HK$11.75/share, with turnover of HK$206 million. The stock gave back most of the prior session's gains as the positive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105001263","title":"Movement Alert｜TransThera Sciences-B Rises 19.89% in Regular Trading, Company Announces Up to RMB 100 Million H-Share Buyback Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1105001263","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105001263?lang=en_us&edition=fundamental","pubTime":"2026-06-29 10:06","pubTimestamp":1782698781,"startTime":"0","endTime":"0","summary":"On June 29, TransThera Sciences-B rose 19.89% in regular trading, trading at HKD 10.85/share, with turnover of HKD 187 million.On the news front, the company announced on June 28 that its Board of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647342670","title":"Transthera Sciences Jumps Most in Nearly Four Months on Share Buyback Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2647342670","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647342670?lang=en_us&edition=fundamental","pubTime":"2026-06-29 10:05","pubTimestamp":1782698728,"startTime":"0","endTime":"0","summary":"BUZZ-TransThera Sciences jumps most in nearly four months on share buyback plan** Shares of TransThera Sciences  Inc2617.HKjump 21.3% to HK$11.04, on course for their biggest one-day pct gain since March 6** Stock hits the highest level since June 24, on track to snap five straight sessions of falls** China-based co says it intends to repurchase shares in the open market for up to 100 mln yuan  to demonstrate its confidence in its own business outlook and prospects** Co develops innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases** YTD, stock down 90.4%, Hang Seng Biotech Index.HSBIOdown 13.6%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL1N43100Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187523767","title":"HK Movers | Hong Kong Biotech Sector Strengthened; TRANSTHERA Rose More Than 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187523767","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187523767?lang=en_us&edition=fundamental","pubTime":"2026-06-29 09:51","pubTimestamp":1782697878,"startTime":"0","endTime":"0","summary":"Hong Kong biotech sector strengthened;  $TRANSTHERA-B(02617)$  rose nearly 20%,  $HUA MEDICINE-B(02552)$  gained over 7%, and  $XTALPI(02228)$  and  $JOINN(06127)$  also advanced.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02552","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103412748","title":"TRANSTHERA-B Announces Market Buyback Plan Under General Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1103412748","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103412748?lang=en_us&edition=fundamental","pubTime":"2026-06-28 21:00","pubTimestamp":1782651630,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (HKEX: 02617) has issued an announcement regarding its intention to repurchase shares on the open market.In accordance with the general mandate for H-share repurchases approved by the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188827955","title":"TransThera Sciences plans on-market buyback of up to RMB100.00 million under existing mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1188827955","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188827955?lang=en_us&edition=fundamental","pubTime":"2026-06-28 18:23","pubTimestamp":1782642225,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (the “Company”) has announced its intention to repurchase H shares on the open market for an aggregate amount not exceeding RMB100.00 million, or the equivalent in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":147,"code":"91000000","status":"200"}]}}